Cargando…

Systematic Review and Meta-Analysis on the Role of Chemotherapy in Advanced and Metastatic Neuroendocrine Tumor (NET)

BACKGROUND/OBJECTIVES: In the era of somatostatin analogues and targeted therapies, the role of chemotherapy in NET remains largely undefined. This systematic review aimed to assess the effect of chemotherapy on response rates (RR), progression-free survival (PFS), overall survival (OS) and toxicity...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wong, Matthew H., Chan, David L., Lee, Adrian, Li, Bob T., Lumba, Sumit, Clarke, Stephen J., Samra, Jaswinder, Pavlakis, Nick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4928873/ https://www.ncbi.nlm.nih.gov/pubmed/27362760 http://dx.doi.org/10.1371/journal.pone.0158140

Ejemplares similares

Diagnostic Accuracy of Imaging Modalities in the Evaluation of Vascular Invasion in Pancreatic Adenocarcinoma: A Meta-Analysis
por: Li, Angela E., et al.
Publicado: (2013)

Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic Significance
por: Chan, David LH, et al.
Publicado: (2017)

The role of diagnostic, prognostic, and predictive biomarkers in the management of early pancreatic cancer
por: Maloney, Sarah, et al.
Publicado: (2023)

Identification of Novel Biomarkers in Pancreatic Tumor Tissue to Predict Response to Neoadjuvant Chemotherapy
por: Sahni, Sumit, et al.
Publicado: (2020)

Somatostatin Receptor SSTR-2a Expression Is a Stronger Predictor for Survival Than Ki-67 in Pancreatic Neuroendocrine Tumors
por: Mehta, Shreya, et al.
Publicado: (2015)

Dramatic response to selective internal radiation therapy for unresectable hepatocellular carcinoma
por: Park, Woo Daniel, et al.
Publicado: (2015)

Enduring complete metabolic response in metastatic adenocarcinoma of the gastro-oesophageal junction
por: Li, Minmin, et al.
Publicado: (2014)

Gene expression profiling of pancreatic ductal adenocarcinomas in response to neoadjuvant chemotherapy
por: Sahni, Sumit, et al.
Publicado: (2023)

Anti-PD-1 Monoclonal Antibodies (mAbs) Are Superior to Anti-PD-L1 mAbs When Combined with Chemotherapy in First-Line Treatment for Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Network Meta-Analysis
por: Wei, Joe Q., et al.
Publicado: (2023)

Small Molecule KRAS Inhibitors: The Future for Targeted Pancreatic Cancer Therapy?
por: Gillson, Josef, et al.
Publicado: (2020)

The Prognostic and Predictive Role of the Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Lymphocyte-to-Monocyte Ratio (LMR) as Biomarkers in Resected Pancreatic Cancer
por: Maloney, Sarah, et al.
Publicado: (2023)

Optimal Upfront Treatment in Surgically Resectable Pancreatic Cancer Candidates: A High-Volume Center Retrospective Analysis
por: Maloney, Sarah, et al.
Publicado: (2021)

Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature
por: Chan, David L., et al.
Publicado: (2015)

Autophagy: A Key Player in Pancreatic Cancer Progression and a Potential Drug Target
por: Gillson, Josef, et al.
Publicado: (2022)

Correction: Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature
por: Chan, David L., et al.
Publicado: (2015)

Life-threatening diarrhea in neuroendocrine tumors: two case reports
por: Gordon, Emma, et al.
Publicado: (2021)

Evolution in functionality of a metastatic pancreatic neuroendocrine tumour (pNET) causing Cushing’s syndrome: treatment response with chemotherapy
por: Rajeev, Surya Panicker, et al.
Publicado: (2014)

Treatment and Prevention of Bone Metastases from Breast Cancer: A Comprehensive Review of Evidence for Clinical Practice
por: Li, Bob T., et al.
Publicado: (2014)

The role of staging laparoscopy in pancreatic adenocarcinoma and its effect on patients’ survival
por: Jambor, Maxwell A., et al.
Publicado: (2022)

The Right Treatment Strategy for the Right Patient: A Biomarker-Driven Approach to Neoadjuvant vs. Surgery-First Management of Resectable and Borderline Resectable Pancreatic Cancer
por: Nahm, Christopher B., et al.
Publicado: (2022)

The unmet information needs, quality of life, and care experiences of patients with neuroendocrine tumours (NETs) at follow-up: 6 months from diagnosis
por: Guccione, Lisa, et al.
Publicado: (2023)

FOLFOX‐bevacizumab chemotherapy in patients with metastatic neuroendocrine tumors
por: Lacombe, Caroline, et al.
Publicado: (2023)

Immunotherapy for Aggressive and Metastatic Pituitary Neuroendocrine Tumors (PitNETs): State-of-the Art
por: Feola, Tiziana, et al.
Publicado: (2022)

Multivisceral resection of pancreatic neuroendocrine tumours: a report of two cases
por: Gundara, Justin S, et al.
Publicado: (2011)

First-line chemotherapy in patients with metastatic gastroenteropancreatic neuroendocrine carcinoma
por: Bongiovanni, Alberto, et al.
Publicado: (2015)

New drug developments in metastatic gastric cancer
por: Tan, Aaron C., et al.
Publicado: (2018)

Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumours (NET): guidelines from the NET-Liver-Metastases Consensus Conference
por: Kennedy, Andrew, et al.
Publicado: (2015)

Streptozocin chemotherapy for advanced/metastatic well-differentiated neuroendocrine tumors: an analysis of a multi-center survey in Japan
por: Aoki, Taku, et al.
Publicado: (2014)

Systemic chemotherapy with FOLFOX in metastatic grade 1/2 neuroendocrine cancer
por: Faure, Marjorie, et al.
Publicado: (2017)

Genomic Profiling of Metastatic Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients in the Personalized-Medicine Era
por: Kim, Seung Tae, et al.
Publicado: (2016)

Current treatment strategies for patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
por: Uri, Inbal, et al.
Publicado: (2018)

Systemic Treatment Selection for Patients with Advanced Pancreatic Neuroendocrine Tumours (PanNETs)
por: Megdanova-Chipeva, Vera G., et al.
Publicado: (2020)

Osteoclast inhibitors to prevent bone metastases in men with high-risk, non-metastatic prostate cancer: A systematic review and meta-analysis
por: Hayes, Aimee R., et al.
Publicado: (2018)

Neuroendocrine tumors (NETs) – experience of a single Center
por: Şincu, Mihaela Cornelia, et al.
Publicado: (2021)

A pancreatic mixed neuroendocrine-non-neuroendocrine neoplasms (MiNEN) (NET and undifferentiated carcinoma of the pancreas with osteoclast-like giant cells) with metastatic neuroendocrine component to the liver
por: Gao, Guofeng, et al.
Publicado: (2020)

Single-centre experience with peptide receptor radionuclide therapy for neuroendocrine tumours (NETs): results using a theranostic molecular imaging-guided approach
por: Gordon, S., et al.
Publicado: (2023)

Platinum-doublet chemotherapy for advanced gastroenteropancreatic neuroendocrine carcinoma: a systematic review and meta-analysis
por: Ohmoto, Akihiro, et al.
Publicado: (2022)

Identifying and Prioritizing Gaps in Neuroendocrine Tumor Research: A Modified Delphi Process With Patients and Health Care Providers to Set the Research Action Plan for the Newly Formed Commonwealth Neuroendocrine Tumor Collaboration
por: Segelov, Eva, et al.
Publicado: (2016)

Malignant Cardiac Tamponade from Non-Small Cell Lung Cancer: Case Series from the Era of Molecular Targeted Therapy
por: Li, Bob T., et al.
Publicado: (2014)

Radiomics in pulmonary neuroendocrine tumours (NETs)
por: Cozzi, Diletta, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1oid7sj2m13e9n7j0l87faah9c